Company
Grail Q1 Revenues up 19 Percent Driven by Clinical Test Growth
Grail shared new results from the NHS trial of its Galleri screening test, which brought in $29.1 million in Q1, a 24 percent increase over the same quarter last year.
Seer Q1 Revenues Rise 35 Percent
The proteomics firm's product revenues grew 71 percent year over year to $2.9 million while its service revenue grew nearly threefold to $1.2 million.
Biodesix Q1 Revenues up 21 Percent as Firm Slashes Full-Year Guidance on Sales Restructuring
Biodesix revised its full-year revenue guidance downward to a range of $80 to $85 million from a previous range of $92 million to $95 million as it restructures its sales force.
Following a joint statement from the two countries on Monday, stocks of major life sciences tool and diagnostic companies rallied.
Grail, Athenahealth Ink Deal to Facilitate Liquid Biopsy Test Ordering
The integration will enable more than 160,000 US clinicians on the Athenahealth network to "opt in to more seamlessly order Galleri directly in the EHR," Grail said in a statement.